Coya Therapeutics, Inc.

NasdaqCM:COYA Stock Report

Market Cap: US$109.1m

Coya Therapeutics Management

Management criteria checks 1/4

Coya Therapeutics' CEO is Arun Swaminathan, appointed in Nov 2024, has a tenure of less than a year. directly owns 0.06% of the company’s shares, worth $65.30K. The average tenure of the management team and the board of directors is 1.6 years and 3.7 years respectively.

Key information

Arun Swaminathan

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.06%
Management average tenure1.6yrs
Board average tenure3.7yrs

Recent management updates

Recent updates

Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth

Oct 29
Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

Oct 13

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Mar 26
Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

Feb 13

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position

Jan 13

We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

Sep 06
We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

May 17
Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

CEO

Arun Swaminathan

less than a year

Tenure

Dr. Arun Swaminathan, Ph.D. is Chief Executive Officer of Coya Therapeutics, Inc. from November 1, 2024. Dr. Swaminathan was Chief Business Officer of Coya Therapeutics, Inc. from August 2024 to November 1...

Leadership Team

NamePositionTenureCompensationOwnership
Howard Berman
Executive Chair5.1yrsUS$1.32m5.68%
$ 6.2m
Fred Grossman
President & Chief Medical Officer1.6yrsUS$862.61k0.016%
$ 17.7k
David Snyder
CFO & COO2.9yrsUS$947.89k0.053%
$ 57.5k
Arun Swaminathan
Chief Executive Officerless than a yearno data0.060%
$ 65.3k
Gregory MacMichael
Chief Technical Officer3.3yrsno datano data
Michelle Frazier
Senior Vice President of Regulatory Affairs1.7yrsno datano data
Aaron Thome
Head of Neuroinflammation Platformno datano datano data
Karen King
Senior VP of Program Management & Clinical Operationsless than a yearno datano data

1.6yrs

Average Tenure

63yo

Average Age

Experienced Management: COYA's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Howard Berman
Executive Chair5.1yrsUS$1.32m5.68%
$ 6.2m
Dov Goldstein
Independent Director3.9yrsUS$63.75k0.060%
$ 65.3k
Wilbur Ross
Independent Director1.2yrsno data0.99%
$ 1.1m
Stanley Appel
Member of Scientific Advisory Boardno datano datano data
Lawrence Steinman
Member of Scientific Advisory Boardno datano datano data
Malcolm Brenner
Member of Scientific Advisory Boardno datano datano data
Ann Lee
Independent Director3.7yrsUS$52.50k0.13%
$ 146.8k
Merit Cudkowicz
Clinical Advisor1.6yrsno datano data
Dieter Weinand
Independent Director1.5yrsUS$44.16kno data
Anabella Villalobos
Independent Director3.8yrsUS$53.75k0.060%
$ 65.3k
Shimon Sakaguchi
Member of Scientific Advisory Boardno datano datano data
Clive Svendsen
Member of Scientific Advisory Boardno datano datano data

3.7yrs

Average Tenure

64yo

Average Age

Experienced Board: COYA's board of directors are considered experienced (3.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 23:47
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Coya Therapeutics, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas ShraderBTIG
Keay NakaeChardan Capital Markets, LLC
Jason KolbertD. Boral Capital LLC.